Anavex Life Sciences (AVXL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $42.00 price target.
Ram Selvaraju has given his Buy rating due to a combination of factors that highlight the promising potential of Anavex Life Sciences’ drug, blarcamesine, in treating Alzheimer’s disease. The recent open-label extension data from the ATTENTION-AD trial demonstrated significant therapeutic benefits, showing that continuous treatment with blarcamesine led to meaningful improvements in clinical decline for early Alzheimer’s patients over a four-year period.
Additionally, the trial results indicated a favorable safety profile, with no serious neuroimaging adverse events or deaths related to the drug. The delayed-start analysis further underscored the advantages of early treatment initiation, as participants who started blarcamesine earlier showed greater cognitive stability compared to those who began treatment later. These findings suggest that blarcamesine may have disease-modifying effects, reinforcing the Buy rating and supporting a 12-month price target of $42.